Dynavax Announces Third Quarter 2004 Financial Results Conference Call and Webcast

November 8, 2004 at 12:00 AM EST
Dynavax Announces Third Quarter 2004 Financial Results Conference Call and Webcast

BERKELEY, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced that Company executives will hold a conference call to discuss Dynavax's third quarter 2004 financial results on Monday, November 8, 2004 at 5:00 p.m. ET. A press release outlining third quarter 2004 results will be issued prior to the call.

Interested parties may listen to the webcast live at http://www.dynavax.com . The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).

Additionally, a telephonic replay will be available through November 15, 2004 by dialing 888-286-8010, conference identification number 93697898. International callers can dial 617-801-6888, conference identification number 93697898.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three initial indications: ragweed allergy immunotherapeutic, currently in a Phase 2/3 clinical trial; a hepatitis B vaccine that has completed a Phase 2 clinical trial; and an asthma immunotherapeutic that has completed a Phase 2 exploratory trial.

SOURCE Dynavax Technologies Corporation
10/27/2004 CONTACT: Jane M. Green, Ph.D., Vice President, Corporate Communications of Dynavax Technologies Corporation, 510-665-4630, or jgreen@dvax.com
Web site: http://www.dynavax.com

11/08/2004 16:00 EST http://www.prnewswire.com